None
Quote | CareDx Inc. (NASDAQ:CDNA)
Last: | $7.56 |
---|---|
Change Percent: | 2.26% |
Open: | $7.8 |
Close: | $7.56 |
High: | $7.8 |
Low: | $7.53 |
Volume: | 555,244 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | CareDx Inc. (NASDAQ:CDNA)
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announ...
2024-04-17 16:00:04 ET Mason Carrico from Stephens issued a price target of $15.00 for CDNA on 2024-04-17 14:04:00. The adjusted price target was set to $15.00. At the time of the announcement, CDNA was trading at $8.29. The overall price target consensus is at $39.50 wi...
Message Board Posts | CareDx Inc. (NASDAQ:CDNA)
Subject | By | Source | When |
---|---|---|---|
$CDNA short data if anyone is interested | Porterhouse10 | investorshub | 07/04/2023 6:51:12 AM |
MomentumIts gaining | ClayTrader | investorshub | 06/28/2023 8:06:47 AM |
Price trading | stocktrademan | investorshub | 06/26/2023 1:57:02 AM |
$CDNA got some short data | stocktrademan | investorshub | 06/25/2023 12:04:58 PM |
The trading | TREND1 | investorshub | 06/24/2023 10:05:41 PM |
News, Short Squeeze, Breakout and More Instantly...
CareDx Inc. Company Name:
CDNA Stock Symbol:
NASDAQ Market:
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announ...
2024-04-17 16:00:04 ET Mason Carrico from Stephens issued a price target of $15.00 for CDNA on 2024-04-17 14:04:00. The adjusted price target was set to $15.00. At the time of the announcement, CDNA was trading at $8.29. The overall price target consensus is at $39.50 wi...
CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients – has appointed John W. Hanna...